Annexon Inc (NASDAQ: ANNX) — Company Overview, News & Financial Data
Annexon is a biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative disorders targeting key immune pathways.
Annexon Inc
Annexon (NASDAQ:ANNX) is a biopharmaceutical company focused on developing novel therapies for patients with autoimmune and neurodegenerative disorders. Their innovative approach targets the classical complement cascade, a crucial part of the immune system, aiming to halt or prevent the progression of these conditions. The company's portfolio includes several candidates in clinical trials, targeting diseases like Guillain-Barre Syndrome, amyotrophic lateral sclerosis (ALS), and Huntington's disease, among others. With a commitment to transforming the lives of patients through groundbreaking research, Annexon's objective is to pioneer treatments that can significantly improve outcomes for individuals facing these challenging diseases.
Snapshot
Operations
Products and/or services of Annexon Inc
- ANX005: This drug candidate is likely in development for treating a specific classical complement-mediated disorder.
- ANX007: Similar to ANX005, this is an investigational drug candidate targeting another classical complement-mediated disorder.
- ANX1502: This candidate focuses on a different approach. It might be an oral small molecule inhibitor of the classical complement pathway, potentially for a broader range of classical complement-mediated disorders compared to ANX005 or ANX007.
- ANX009: This investigational drug candidate is likely targeted towards a specific classical complement-mediated disease affecting the eye or surrounding tissues (ophthalmic disease).
Annexon Inc executive team
- Douglas E. LoveCEO, President & Director
- Jennifer LewExecutive VP, CFO & Corporate Secretary
- Ted YednockExecutive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
- Dean R. ArtisChief Scientific Officer & Executive VP
- Linda A. FitzpatrickChief Human Resources Officer
- Michael OverdorfExecutive VP & Chief Business Officer
- Henk-Andre KroonSenior Vice President of Translational Medicine
- Jamie DananbergExecutive VP & Chief Medical Officer
- Shikhar AgarwalSenior VP & Head of Commercial
- Sunil MehtaSenior VP of Medical Affairs
Latest news about Annexon Inc
Key financials
Reported results for Annexon Inc, in USD.
- Market cap
- 712.8M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -216.4M | -206.7M | |
| 0 | -154.1M | -138.2M | |
| 0 | -143.7M | -134.2M | |
| 0 | -145.6M | -138.3M |